Established in 1952, the Department of Cardiovascular Medicine of Jiangsu Province Hospital is a traditional preponderant discipline which is among the first batch in China authorized to offer master’s and doctorate degrees. It was rated as a Key Discipline in 2007 and a Key Clinical Specialty both of the national level, embracing three training bases for coronary heart disease, cardiac arrhythmia and congenital heart disease which are involved with National Health and Family Planning Commission of China.
The Department has 15 PhD supervisors and 18 postgraduate supervisors, five experts entitled with special allowance of the State Council, one Vice Chairman of Chinese Medical Association of the second grade, four members of the Standing Committee and nine Committee members of that Association. Two experts in this department hold the position of Chairman of the Specialized Branch of Jiangsu Medical Association and one expert has been accepted by the National New Century Talents Project.
Prof. Xiangqing Kong, MD, PhD
President of The First Clinical Medical School of Nanjing Medical University
Director And Professor of Department of Cardiovascular Medicine
Chief Physician of Department of Cardiovascular Medicine
Professor Xiangqing Kong is the supervisor of doctorate candidate of the First Affiliated Hospital of Nanjing Medical University. He also serves as a fellow of Society for Cardiovascular Angiography and Interventions (FSCAI), fellow of the American College of Cardiology (FACC) of USA and European Society of Cardiology (ESC), Vice Chairman of Chinese Society of Biomedical Engineering, fellow of Chinese Society of Cardiology and group leader of structural heart disease task force, Chairman of Jiangsu Provincial Society of Cardiology. His major research fields are interventional cardiology and hypertension therapy focused on caterther based therapy of structural heart disease and device therapy for resistant hypertension.
During 2001-2012, Prof. Kong successfully led his team to develop the world's first symmetric ventricular septal defect occluder and occluder with bioceramic coatings. He also developed supporting technology for interventional treatment. The devices and technology he introduced has been promoted to more than 30 countries and regions, winning him the second prize of the 2014 National Technology Invention Award and the first prize of Science & Technology Achievement of the Ministry of Education of the year 2013.
In the past several years, 6 national invention patents of him have been authorized and more than 60 of his scientific papers have been published. Among them, with Prof Kong as the first and correspondent author, 15 papers were published by SCI. In 2016, funded by the Project of Major Scientific Instrument of National Natural Science Foundation of China (NSFC), he focused on the research and development of the first device of power ultrasonic hypertension in the world. Over the past 15 years of research, he has accumulated abundant experience in interdisciplinary collaboration, achievements transformation and so on, forming an effective mechanism for synergy innovation .
The Department is a specialty project for cardiovascular disease of National Drug Clinical Research Institution, Clinical Medical Center of Cardiovascular Disease Jiangsu Province and Center of Heart Intervention of Jiangsu Province.
It integrates five platforms, including Engineering Center for Diagnosis and Treatment of Cardiovascular Disease of Jiangsu Province, Cerebrovascular and Cardiovascular Disease Center of Jiangsu Province, Alliance of the Diagnosis and Treatment of Cerebrovascular and Cardiovascular Disease, Chest Pain Center of Jiangsu Province and Center of Cerebral Stroke of Jiangsu Province, and boasts five treatment systems for major cerebrovascular and cardiovascular diseases incorporating prevention, diagnosis, therapy, and rehabilitation.
The Department has been involved in the research and development of innovative devices for the diagnosis and therapy of major cardiovascular diseases since 2014 and initially completed the construction of animal laboratory, which has greatly intensified the Department comprehensive strengths.
Medical Conditions Treated in Department of Cardiovascular Medicine Include:
Coronary Heart Disease
Congenital Heart Disease
Valvular Heart Disease (VHD)
Complicated Heart Disease
Pulmonary Arterial Hypertension
Ventricular/Atrial Premature Beat
Ventricular/Atrial Septal Defect
Patent Ductus Arteriosus (PDA)
Sick Sinus Syndrome (SSS)
The Department of Cardiovascular Medicine has been making continued efforts in making exchanges with international organizations. It has established long-term and stable partnerships with Harvard University, Stanford University and ICI meeting of Israel, covering such areas as hypertension, stem cells and molecular imaging.
While introducing advanced international technologies and concepts, the Department has made persistent efforts in applying innovative foreign products in cardiovascular field in China and improving its ability to transform innovative concepts into practices. It has secured initial achievements in several featured novel devices, including world’s first power ultrasonic cardiovascular therapeutic instrument, advanced extracorporeal cardiac pump. It has also completed phase two clinical research of biological target therapy for ischemic heart disease.